# Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

> **NCT00515827** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 53 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir (MK-0518)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00515827
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-09
- **Final completion:** 2008-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515827, "Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00515827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*